Macro
Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.
month values ▾
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +0.10 | +0.10 | +0.10 | +0.00 | +0.00 | +0.18 | +0.31 | -0.10 | -0.10 | -0.10 | +0.00 | +0.00 |
The sector sentiment is neutral despite Pfizer’s $60 billion acquisition of Pharmacia, a move that signals confidence in large-scale consolidation and pipeline expansion. While the deal underscores continued strategic ambition in the pharmaceutical space, broader healthcare performance remains weighed by lackluster movement in other sub-sectors and no accompanying regulatory or reimbursement tailwinds. The positive impact of the merger is thus offset by overall stagnation across the sector.
How this mood is scored ▾
Federal agents charged Sam Waksal with insider trading ahead of the Erbitux rejection, and questions spread to celebrity friend Martha Stewart. The saga personified the insider-dealing outrage of the scandal era.
Pfizer is acquiring rival Pharmacia in a $60 billion stock-for-stock transaction, combining two major pharmaceutical firms to strengthen global R&D and commercial scale. The merger, expected to yield $2.5 billion in annual cost savings by 2005, unites key patented drugs like Lipitor, Viagra, Celebrex, and Bextra, enhancing Pfizer's pipeline and market leadership. The deal follows Pharmacia's spin-off of Monsanto and positions Pfizer for long-term industry dominance amid rising R&D costs and demand for innovative therapies.